Stay updated with breaking news from Gregory Riely. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pfizer Inc. said Thursday the U.S. Food and Drug Administration has approved its Braftovi plus Mektovi combination therapy as a treatment for patients with...
Encorafenib (Braftovi; Pfizer Inc) and binimetinib (Mektovi; Pfizer Inc) approved for the treatment of patients with metastatic non-small cell lung cancer who harbor a BRAF V600E mutation.
Pfizer Inc (NYSE:PFE) announced that the United States Food and Drug Administration (FDA) has approved BRAFTOVI (encorafenib) plus MEKTOVI (binimetinib) for...
Encorafenib plus binimetinib led to 75% ORR in untreated patients, 59% in treated patients
The combination of Braftovi (encorafenib) plus Mektovi (binimetinib) is approved for metastatic NSCLC with a BRAF V600E mutation.